IPX: Hannigan buys EUR 1.65m as titanium peers lag

Tronox and Chemours still own the old titanium trade

The titanium complex is still a business of scale, chemistry, and patience. Tronox Holdings and The Chemours Company remain the names with the industrial footprint, the pigment reach, and the kind of operating history that makes institutions comfortable enough to own them through a cycle. IperionX is trying to do something narrower and more ambitious at the same time, build a U.S.-based low-carbon titanium supply chain from its Titan project in Tennessee, and that puts it in a different lane from the incumbents.

That difference matters because the market is not paying for a generic titanium story right now. It is paying for policy support, domestic supply security, and the possibility that a smaller name can turn process advantage into strategic relevance. The backdrop is mixed. The Federal Reserve has held rates steady at 3.50% to 3.75% through its June 2026 meeting, and equity leadership has rotated toward infrastructure, defense, and energy transition themes. Critical minerals have benefited from that rotation, but the commodity side is not handing out easy wins. That is the frame you need before you look at the filings.

July 13 buying cluster, not a lone print

The first thing to notice is that this was not a single director nibbling at a thin line. Todd Hannigan, the executive chairman, bought shares in two transactions on July 13, and CEO Anastasios Arima bought shares the same day. That is a cluster, and our data treats it that way because multiple insiders trading the same name within a month usually tells you more than one isolated line item.

The euro-normalised filing values are large enough to matter in context. Hannigan bought roughly EUR 944,065 in one transaction and EUR 703,329 in another, while Arima bought about EUR 434,329. Those are not symbolic purchases. They are open-market buys from the top of the house, and they came after earlier July 10 buys by the same executives, which makes the pattern less easy to write off as a one-off reaction to a headline.

IperionX versus the incumbents, scale versus process

Tronox and Chemours are the obvious comparison points because they sit on the mature side of the titanium market. They have global operations, established customer relationships, and the kind of scale that lets them absorb bad pricing periods better than a smaller developer can. ATI Inc. is another useful reference, though it lives further downstream in titanium alloys and serves aerospace and defense with a more mature industrial base. IperionX is not trying to be any of those companies. It is trying to be the domestic processing story that can win on technology, not breadth.

That is why the company’s pitch is so tied to its patented low-energy, low-emission approach, closed-loop recycling, and U.S. feedstock. If that works, the market can re-rate the name on strategic value as much as on near-term revenue. If it does not, you are left with a development-stage materials company competing against better capitalized peers in a sector where execution still beats narrative. The comparison is useful because it keeps the filing in proportion. A chairman buy at a small-cap materials name is not the same thing as a buy at a cash-rich incumbent with a dividend and a fortress balance sheet.

The macro backdrop helps IperionX more than it helps the old guard. Government efforts to reduce reliance on concentrated overseas supply, especially from China and Russia, have made domestic critical minerals and processing a policy theme rather than a niche industrial story. That does not make the stock cheap. It does make the company legible to a different kind of buyer, one who cares about supply chain security, defense relevance, and the possibility of domestic substitution.

July 7 offering and the insider read

The timing matters. These July 13 purchases followed the company’s July 7 pricing of an underwritten public offering of American Depositary Shares. That is the part you cannot ignore, because insider buying after an offering can mean different things depending on the setup. Sometimes it is a clean expression of confidence after dilution. Sometimes it is a way to signal that management thinks the market has overdone the discount. Sometimes it is simply what happens when insiders are allowed back in the market and choose to buy.

Here the sequence leans toward the first two interpretations. The chairman and CEO were already buying on July 10, then they added again on July 13. That is a deliberate pattern, not a reflex. Our scoring lands at 58, helped by the chief executive role, the cluster, and the size of the purchases relative to market value. The company’s market cap in the dossier is EUR 858.5 million, so Hannigan’s larger purchase alone was about 0.11% of market value. That is enough to register as a real allocation of capital, not a token gesture.

The market still has to decide whether the offering reset the stock to a more workable level or simply gave insiders a better entry point. The filing does not answer that. It does tell you that the top of the house was willing to buy into the post-offering tape rather than wait for cleaner conditions.

Cohort data says decent, not decisive

Insiders Trades data puts this in the bucket of chief-executive buys at sweet-spot names between EUR 300 million and EUR 1 billion in market value. That bucket has a 90-day historical win rate of 46.3% and an average return of 0.2%, with a 365-day average return of 18.01%. Read that carefully. It is historical cohort data, not a forecast for IperionX, and it does not promise anything about this specific trade.

The point of the bucket is narrower. CEO buying in this size range has historically been a better hunting ground than random insider activity at very large names, where the market often prices the information faster and the signal gets diluted by scale. But the cohort is not a magic wand. A 46.3% win rate is close to a coin flip, and the 90-day average return of 0.2% is basically flat. If you want a clean, easy edge, this is not it. If you want a disciplined way to separate meaningful buying from background noise, it helps.

That is also why the cluster matters more than the score itself. The score is a filter, not a verdict. A chief executive buying once is one thing. A chairman and CEO buying in the same window, after earlier July 10 purchases, is a different pattern. It does not guarantee follow-through, but it does tell you the people with the most direct line of sight to the business were willing to put fresh capital into the stock.

Domestic titanium is the story, but execution still pays the bill

The sector case for IperionX is straightforward enough to fit on one page. Titanium demand is tied to aerospace, defense, electric vehicles, additive manufacturing, and consumer electronics, while the broader titanium minerals market is supported by construction demand for titanium dioxide pigments and the push for lighter, stronger alloys. The policy case is equally clear. The U.S. wants more domestic processing and less dependence on concentrated foreign supply.

The problem is that every one of those themes still has to be converted into operating progress. That is where the comparison with ATI becomes useful again. ATI already has downstream capability and a more mature industrial profile. Tronox and Chemours have scale and customer reach. IperionX has to prove that its process advantage can become commercial advantage. The insider cluster says management is willing to buy that bridge. It does not build it for them.

You can see why the market might give the stock some room anyway. Smaller materials names tied to strategic supply chains can move on a narrower set of milestones than diversified peers. A permitting step, a financing event, a production update, or a customer win can matter more here than a broad sector rerating. That cuts both ways. Good news can reprice the stock quickly. Bad execution can do the same.

Filing pattern and recent declarations

The July 13 activity is more interesting because of the pattern than because of any single dollar amount. Hannigan bought twice on the same day. Arima bought the same day. Both had already bought on July 10. That is a repeated commitment over a short window, and repeated commitment is usually the cleaner read than a one-day burst.

The internal dossier also shows a broader recent declaration pattern, with seven recent declarations and three distinct insiders in the cluster picture. Marcela Rocha Castro appears in the recent history as a CFO-level other transaction on April 30, while Hannigan and Arima show up repeatedly on the buy side. That is not a broad board-wide stampede, and it should not be read that way. It is a concentrated pattern at the top of the company, which is exactly where you would expect the most informed capital allocation decisions to show up if management thought the post-offering setup was attractive.

There is still a risk of over-reading it. Insiders buy for many reasons, and the market has a habit of turning a clean filing into a grand thesis. Do not do that here. The better read is narrower. The chairman and CEO bought after an offering, in a name that sits in a policy-supported but execution-heavy corner of the materials market, while the larger incumbents still dominate the old titanium trade. That is enough to matter. It is not enough to settle the case.

What to watch while Tronox and Chemours keep the lead

The next few checkpoints are concrete. First, watch whether the company follows the July 7 offering with operational updates that show the capital raise was tied to progress rather than just runway. Second, watch whether the insider pattern extends beyond July 13, because repeated buying over multiple windows is more informative than a single burst. Third, watch how the stock trades relative to the larger titanium names. If Tronox and Chemours stay range-bound while IperionX holds its post-offering level, the market is telling you it is willing to pay for the domestic processing angle.

The comparison also gives you a way to keep your expectations honest. Tronox and Chemours are not going to be judged on whether they can invent a new supply chain. They are judged on margins, pricing, and cycle management. IperionX is judged on whether it can turn a differentiated process into a durable industrial business. That is a harder job, and the market knows it. Which is why the chairman buying EUR 944,065 and EUR 703,329, with the CEO adding EUR 434,329, is worth attention without being over-sold.

The stock now has a simple test. If management keeps buying and the company keeps converting the Titan project into visible operating progress, the July cluster will look like a sensible top-of-house vote. If the next updates stall, the filing will still be real, but it will sit in the long list of insider buys that arrived before the market had enough evidence to agree.

Dig deeper: IPERIONX Ltd's full insider filing history.

This is not investment advice.